Haemonetics Co. (NYSE:HAE) has received an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $111.00.

A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price on the stock in a research report on Friday, October 12th. Barrington Research reiterated a “buy” rating and issued a $127.00 target price on shares of Haemonetics in a research report on Friday, October 5th.

Haemonetics stock opened at $99.78 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.92. The firm has a market cap of $5.28 billion, a PE ratio of 53.36, a P/E/G ratio of 3.51 and a beta of 1.07. Haemonetics has a fifty-two week low of $60.51 and a fifty-two week high of $117.56.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The firm had revenue of $241.58 million for the quarter, compared to analysts’ expectations of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted $0.48 EPS. As a group, equities analysts forecast that Haemonetics will post 2.33 earnings per share for the current year.

In other Haemonetics news, CFO William P. Mr. Burke sold 841 shares of the firm’s stock in a transaction on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total value of $39,325.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pedro P. Granadillo sold 12,322 shares of the firm’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $114.50, for a total transaction of $1,410,869.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,855 shares of company stock worth $4,102,035. 1.04% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Belpointe Asset Management LLC grew its holdings in Haemonetics by 1.9% in the 3rd quarter. Belpointe Asset Management LLC now owns 10,041 shares of the medical instruments supplier’s stock worth $1,150,000 after acquiring an additional 192 shares during the last quarter. Retirement Systems of Alabama grew its holdings in Haemonetics by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 67,012 shares of the medical instruments supplier’s stock worth $6,705,000 after acquiring an additional 210 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in Haemonetics by 5.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 12,591 shares of the medical instruments supplier’s stock worth $1,443,000 after acquiring an additional 696 shares during the last quarter. Xact Kapitalforvaltning AB grew its holdings in Haemonetics by 14.7% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 8,595 shares of the medical instruments supplier’s stock worth $985,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Riverhead Capital Management LLC grew its holdings in Haemonetics by 27.8% in the 3rd quarter. Riverhead Capital Management LLC now owns 5,971 shares of the medical instruments supplier’s stock worth $684,000 after acquiring an additional 1,300 shares during the last quarter. 97.56% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: What are retained earnings?

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.